Key result
Troglitazone reduces CIMT progression by ~31% vs placebo in Hispanic women with recent gestational diabetes.
Why the study?
Does troglitazone reduce the progression of carotid intima-media thickness in nondiabetic, Hispanic premenopausal women with recent gestational diabetes?
Population
266 nondiabetic, Hispanic premenopausal women with recent gestational diabetes at high risk for type 2…
Comparison
Troglitazone vs Placebo
Design
RCT, randomized
Authors
Loading...
Supports troglitazone to slow early atherosclerosis in high-risk women; extends insulin-sensitizer effects on CIMT to nondiabetic post-GDM Hispanics.
RCT (n=266)
Does troglitazone reduce the progression of carotid intima-media thickness in nondiabetic, Hispanic premenopausal women with recent gestational diabetes?
Effect estimate: 31% lower
p-value: p=0.048
Troglitazone significantly reduced the progression of subclinical atherosclerosis (measured by CIMT) in high-risk premenopausal Hispanic women, an effect associated with increased insulin sensitivity.
Xiang et al. (2005) conducted an RCT in High risk for type 2 diabetes (n=266). Troglitazone vs. Placebo was evaluated on Progression of carotid intima-media thickness (CIMT) (31% lower, p=0.048). Troglitazone reduced the mean rate of carotid intima-media thickness progression by 31% compared to placebo in nondiabetic Hispanic women with recent gestational diabetes (P=0.048).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: